Oxford Immunotec Schedules Third Quarter 2018 Earnings Release and Business Update Conference Call for November 9, 2018

Udgivet den 06-11-2018  |  kl. 22:12  |  

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that it plans to release third quarter 2018 financial results prior to market open on Friday, November 9, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, Rick Altieri, Chief Financial Officer, and Karen Koski, Vice President, Strategy and Investor Relations will host a conference call to review the Company's third quarter 2018 financial results and provide a business update at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.

To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 7673307, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's T-SPOT®.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

CONTACTS:

For Media and Investor Inquiries:
Karen Koski
VP, Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com

\Hugin

Udgivet af: NPinvestordk

Mest læste lige nu

Vestas får 50 megawatt-ordre i Sydkorea
Aktier/tendens: Bavarian og Nilfisk kan få genrejsning i positiv start
Aktier/middag: Bavarian Nordic tager revanche i splittet og lettere negativt C25
Bavarian Nordic: Farlig variant af mpox konstateret for første gang i USA
Bavarian får løftet kursmålet til 360 kr. fra 345 kr. af Nordea efter vildt kursfald
 

Seneste nyheder

08:52 MT Højgaard Q3: Indtjeningsfremgang drevet af den danske forretning
08:26 Aktier/tendens: Stærke regnskaber fra NKT og ALK stjæler opmærksomheden
08:08 GN's anbefaling løftes til "køb" hos europæisk børshus
08:06 NKT OVERBLIK Q3: Bedre tredje kvartal end ventet har drevet oppræcisering
07:53 ALK-Abelló OVERBLIK Q3: Bedre end ventet på både top og bund
07:45 Ambu løftes til "køb" hos Nordea
07:43 Råvarer: Udsigt til større produktion og svag efterspørgsel sænker oliepriserne
07:38 Vestas får sænket anbefalingen til "hold" af tysk finanshus
07:22 Obligationer/tendens: Små renteløft i sigte efter sene amerikanske plusser
07:09 Lundbeck får løftet kursmålet hos Nordea efter regnskab
06:41 Novo får skåret kursmål af Argus
06:40 Asien: Uvished præger aktiehandlen efter amerikanske inflationsdata
06:35 Svitzers kursmål skåret med 20 kr. hos HSBC
06:34 Torm får skåret kursmål til 226,48 kr. af Jefferies
06:32 Asien: Uvished præger aktiehandlen efter amerikanske inflationsdata
06:32 Valuta: Dollar på stærkeste niveau i halvandet år
06:32 USA/T-bond: Korte renter satte sig efter inflationstal - stigning i den lange ende
06:32 USA/lukning: Marginal fremgang onsdag - Amazon i rekord
06:30 Kalender med link - torsdag den 14. november
17:58 Gubra melder om positive resultater fra fase 1-studie med fedmebehandling